UK - HealthQuill

The WHO has reclassified the Covid-19 virus Omicron BA.2.86 mutation as a “variant of interest” after the global health agency reported an 8.9% rise in global prevalence in cases arising in the UK, France and Sweden.

Omicron mutant BA.2.86 reclassified as ‘variant of interest’ by WHO

HQ Team November 29, 2023: The WHO has reclassified the Covid-19 virus Omicron BA.2.86 mutation as a “variant of interest” after the global.

by HealthQuill
November 29, 2023
0 Comments

Chongqing Zhifei Biological Products, the largest Chinese vaccine company by revenue, will buy shingles vaccines from GSK Plc., worth $3 billion to distribute in the Asian country.

Drugs Health Pharma

China’s Zhifei in $3 billion distribution deal with GSK for shingles vaccine

HQ Team October 10, 2023: Chongqing Zhifei Biological Products, the largest Chinese vaccine company by revenue, will buy shingles vaccines from GSK Plc.,.

by HealthQuill
October 10, 2023
0 Comments

Eisai Co., and Biogen Inc., announced that their drug to treat Alzheimer’s disease and cognitive impairment has been approved in Japan.

Drugs Health Pharma

Japan approves Eisai Co, Biogen Inc’s Leqembi for Alzheimer’s

HQ Team September 25, 2023: Eisai Co., and Biogen Inc., announced that their drug to treat Alzheimer’s disease and cognitive impairment has been.

by HealthQuill
September 25, 2023
0 Comments

The UK’s competition regulator, Competition and Markets Authority has provisionally cleared UnitedHealth’s proposed £1.2bn ($1.6 billion) plan to buy EMIS after a probe by an independent panel.

Drugs Health Pharma

UK’s antitrust body provisionally clears $1.6b UnitedHealth-EMIS merger

HQ Team August 11, 2023: The UK’s competition regulator, Competition and Markets Authority has provisionally cleared UnitedHealth’s proposed £1.2bn ($1.6 billion) plan to.

by HealthQuill
August 11, 2023
0 Comments

The WHO has updated the EG.5 variability of the COVID-19 virus to a ‘variant of interest’ — with genetic changes that are predicted or known to affect virus characteristics, such as transmissibility, virulence, antibody evasion, susceptibility to therapeutics and detectability.

Drugs Health Pharma

WHO labels Covid-19 variant EG.5 as ‘variant of interest’; cases rise

HQ Team August 10, 2023: The WHO has updated the EG.5 variability of the COVID-19 virus to a ‘variant of interest’ — with.

by HealthQuill
August 10, 2023
0 Comments

A new mutant of the COVID-19 virus is spreading across the UK rapidly, and the number of people infected with the disease is rising, government data shows.

Drugs Health Pharma

New COVID-19 virus variant cases rising rapidly in England: UK Health

HQ Team August 5, 2023: A new mutant of the COVID-19 virus is spreading across the UK rapidly, and the number of people.

by HealthQuill
August 5, 2023
0 Comments

Humans have an upper critical temperature range of between 45 degrees Celsius and 50 degrees Celsius, and in that range the body stops functioning optimally, researchers reveal.

Climate Health Pharma

British researchers reveal level of heat stress a human body can take

HQ Team July 7, 2023: Humans have an upper critical temperature range of between 45 degrees Celsius and 50 degrees Celsius, and in.

by HealthQuill
July 7, 2023
0 Comments

A public inquiry starts today in Britain, into the nation’s handling of the Covid-19 pandemic, which killed 224,546 people in the country.

Drugs Health Pharma

Britain’s public inquiry into Covid-19 pandemic to start today

HQ Team June 13, 2023: A public inquiry starts today in Britain, into the nation’s handling of the Covid-19 pandemic, which killed 224,546.

by HealthQuill
June 13, 2023
33 Comments

AstraZeneca, a British-Swedish pharmaceutical company, has signed a deal, worth more than $2 billion, with Quell Therapeutics to develop cell therapies for treating autoimmune diseases.

Drugs Health Pharma

AstraZeneca signs $2 billion deal for autoimmune diseases

HQ Team June 9, 2023: AstraZeneca, a British-Swedish pharmaceutical company, has signed a deal, worth more than $2 billion, with Quell Therapeutics to.